华大基因
(300676)
| 流通市值：160.43亿 | | | 总市值：161.71亿 |
| 流通股本：4.13亿 | | | 总股本：4.16亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,825,935,926.99 | 1,871,450,587.02 | 821,250,378.55 | 4,349,637,250.83 |
| 营业收入 | 2,825,935,926.99 | 1,871,450,587.02 | 821,250,378.55 | 4,349,637,250.83 |
| 二、营业总成本 | 2,820,539,450.5 | 1,787,314,627.49 | 786,451,212.44 | 4,110,928,805.35 |
| 营业成本 | 1,548,174,697.1 | 987,547,295.68 | 417,234,775.18 | 2,179,030,515.3 |
| 税金及附加 | 12,759,204.55 | 8,316,310.43 | 3,481,675.16 | 13,748,095.06 |
| 销售费用 | 663,331,251.16 | 398,275,857.99 | 169,892,501.64 | 1,036,291,018.38 |
| 管理费用 | 257,380,577.5 | 169,888,355.82 | 99,667,246.61 | 398,816,233.5 |
| 研发费用 | 398,014,771.1 | 250,247,428.23 | 106,372,298.63 | 528,924,875.44 |
| 财务费用 | -59,121,050.91 | -26,960,620.66 | -10,197,284.78 | -45,881,932.33 |
| 其中:利息费用 | 43,224,369.47 | 33,392,419.72 | 18,288,893.49 | 91,560,413.87 |
| 其中:利息收入 | 100,284,524.92 | 73,537,046.11 | 35,557,009.28 | 152,042,826.96 |
| 加:公允价值变动收益 | -13,673,223.5 | -7,105,994.48 | -4,719,348.15 | -34,357,341.9 |
| 加:投资收益 | -21,845,253.45 | -11,089,127.82 | -1,245,924.99 | 1,284,630.6 |
| 资产处置收益 | 773,029.21 | 2,685,435.04 | 1,523,222.45 | 2,763,827.65 |
| 资产减值损失(新) | -6,428,202.01 | -2,501,207.12 | -2,070,722.7 | -26,661,583.26 |
| 信用减值损失(新) | -105,486,493.69 | -58,184,315.11 | -24,178,404.78 | -69,612,405.77 |
| 其他收益 | 21,564,378.19 | 20,484,900.24 | 14,783,065.16 | 38,523,620.8 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -119,699,288.76 | 28,425,650.28 | 18,891,053.1 | 150,649,193.6 |
| 加:营业外收入 | 1,592,353.27 | 1,275,786.05 | 57,370.45 | 1,803,084.12 |
| 减:营业外支出 | 8,915,521.2 | 4,367,077.27 | 2,910,630.51 | 36,916,740.86 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -127,022,456.69 | 25,334,359.06 | 16,037,793.04 | 115,535,536.86 |
| 减:所得税费用 | -2,842,029.91 | 5,181,131.7 | 3,887,534.61 | 21,853,693.43 |
| 六、净利润 | -124,180,426.78 | 20,153,227.36 | 12,150,258.43 | 93,681,843.43 |
| 持续经营净利润 | -124,180,426.78 | 20,153,227.36 | 12,150,258.43 | 93,681,843.43 |
| 归属于母公司股东的净利润 | -124,166,136.95 | 18,199,776.02 | 12,402,522.05 | 92,900,396.47 |
| 少数股东损益 | -14,289.83 | 1,953,451.34 | -252,263.62 | 781,446.96 |
| (一)基本每股收益 | -0.3 | 0.04 | 0.03 | 0.23 |
| (二)稀释每股收益 | -0.3 | 0.04 | 0.03 | 0.23 |
| 八、其他综合收益 | -30,125,570.13 | 14,384,298.68 | -12,111,219.44 | -29,976,388.36 |
| 归属于母公司股东的其他综合收益 | -28,840,697.44 | 15,140,254.11 | -11,099,784.21 | -28,888,004.95 |
| 九、综合收益总额 | -154,305,996.91 | 34,537,526.04 | 39,038.99 | 63,705,455.07 |
| 归属于母公司股东的综合收益总额 | -153,006,834.39 | 33,340,030.13 | 1,302,737.84 | 64,012,391.52 |
| 归属于少数股东的综合收益总额 | -1,299,162.52 | 1,197,495.91 | -1,263,698.85 | -306,936.45 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-27 | 2024-04-13 |
| 审计意见(境内) | | | | 标准无保留意见 |